Categories:
ANVISA – Public Consultation for Revision of RDC 47/2009, which establishes the rules for drug package leaflet
On December 2020, ANVISA published the Public Consultation for Revision of DRC Nº 47 of [...]
Ler mais
ANVISA – Resolution RDC 753/2022 – Review to RDC 200/2017 – Marketing Authorization of New, Innovative, Generic and Similar Medicinal Products – updated on October 10th, 2022
On October 7, at Public Ordinary Meeting ANVISA 19/2020, it was approved the draft for Public [...]
Ler mais
ANVISA – Questions & Answers on RDC 359/2020, which instituted DIFA and CADIFA for API used in the manufacture of Drug Products
On September 28th, ANVISA published the document Questions & Answers on RDC 359/2020, which [...]
Ler mais
ANVISA – Service Guidance on flows for analysis of drug product application
On September 23, ANVISA published Service Orientation (OS) 90/2020, from the General Management [...]
Ler mais
ANVISA – New Legislation in Pharmacovigilance
On July 29th, it was published on Brazilian Official Gazette (DOU) the RDC Nº 406/2020, [...]
Ler mais
ANVISA – New Public Consultations for Simplified Notification of Low-Risk Medicines
On June 3, two Public Consultations regarding the Simplified Notification of Low Risk Medicines [...]
Ler mais
ANVISA – New Public Consultation to change the rules for drug product labeling
On June 3, three Public Consultations regarding the Labeling of medicines were published in the [...]
Ler mais
ANVISA – New legislation for Analytical Laboratories – updated 7th July
On May 28, RDC 390/2020 was published in Brazilian Federal Register (D.O.U), which establishes [...]
Ler mais
ANVISA – New Proposal for changing Legislation RDC 73/16 (Post-authorization of medicines)
On May 20, ANVISA published the Public Consultation 812/2020, which proposes changes to RDC [...]
Ler mais
ANVISA – Solicita System allows the addition of documents by third-party companies
ANVISA informs that the Solicita System now allows third parties companies to make amendments [...]
Ler mais
ANVISA – Compliance of similar medicines
Anvisa issues Service Orientation N°79/GGMED/DIRE2/ANVISA, of January 29, 2020 and one [...]
Ler mais
ANVISA – Proposal for new Bioavailability/ Bioequivalence (BA/BE) Studies
On January 2, 2020 ANVISA published in the Brazil the Public Consultation Nº 760 which provides [...]
Ler mais